1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 22,600 | 23,200 | 20.12. |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 02.12. | Spyre begins Phase 1 trials for new IBD treatments | 1 | Investing.com | ||
| 02.12. | Spyre startet Phase-1-Studien für neue CED-Behandlungen | 3 | Investing.com Deutsch | ||
| 02.12. | Spyre Therapeutics, Inc.: Spyre Therapeutics Announces First Participants Dosed in Phase 1 Trials of Novel Half-life Extended Anti-TL1A Antibodies | 89 | PR Newswire | Spyre is concurrently advancing two anti-TL1A molecules into first-in-human studies
Preclinical data for both SPY002 molecules demonstrate picomolar potency and... ► Artikel lesen | |
| 19.11. | Spyre Therapeutics announces pricing of $200 million public offering of common stock | 8 | Seeking Alpha | ||
| 19.11. | Spyre Therapeutics Prices Public Offering Of About 7.28 Mln Shares At $27.50/shr | - | RTTNews | ||
| 18.11. | Spyre Therapeutics startet öffentliches Angebot über 200 Millionen US-Dollar | 1 | Investing.com Deutsch | ||
| 18.11. | Spyre Therapeutics launches $200 million public offering | 1 | Investing.com | ||
| SPYRE THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 18.11. | Spyre Therapeutics, Inc. - 10-Q/A, Quarterly Report | - | SEC Filings | ||
| 18.11. | Spyre Therapeutics, Inc. - 10-K/A, Annual Report | - | SEC Filings | ||
| 18.11. | Spyre Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 12.11. | Spyre meldet vielversprechende Phase-1-Ergebnisse für IBD-Therapie | 3 | Investing.com Deutsch | ||
| 12.11. | Spyre reports promising Phase 1 results for IBD therapy | 1 | Investing.com | ||
| 12.11. | Spyre Therapeutics, Inc.: Spyre Therapeutics Announces Positive Interim Results from Phase 1 Healthy Volunteer Trial for SPY001, Its Novel Half-Life Extended anti-a4ß7 Antibody for the Treatment of Inflammatory ... | 98 | PR Newswire | SPY001 was well tolerated with a favorable safety profile consistent with the anti-a4ß7 class
SPY001 pharmacokinetics exceeded expectations with a ~4-fold increase... ► Artikel lesen | |
| 08.11. | Spyre Therapeutics GAAP EPS of -$1.36 | 1 | Seeking Alpha | ||
| 07.11. | Spyre Therapeutics, Inc.: Spyre Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update | 34 | PR Newswire | Continued execution towards expected milestones across portfolio, with SPY001 on-track for interim Phase 1 data by year-end 2024, and SPY002 on-track for initiation... ► Artikel lesen | |
| 07.11. | Spyre Therapeutics, Inc. - S-8, Securities to be offered to employees in employee benefit plans | - | SEC Filings | ||
| 07.11. | Spyre Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 07.11. | Spyre Therapeutics, Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 28.10. | Spyre Therapeutics-Direktor verkauft Aktien im Wert von 10.929 US-Dollar | - | Investing.com Deutsch | ||
| 25.10. | Guggenheim impressed by Spyre's 'diverse' portfolio, lifts shares target to $65 | 2 | Investing.com |
Seite:
1 2 3 Weiter >>
49 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| ORUKA THERAPEUTICS | 19,500 | 0,00 % | Oruka Therapeutics, Inc.: Oruka Therapeutics Announces First Participants Dosed in Phase 1 Trial of ORKA-001, its Novel Half-life Extended Anti-IL-23p19 Antibody | Pharmacokinetic and safety data from healthy volunteers anticipated in the second half of 2025 On track to initiate a proof-of-concept study in psoriasis in the second half of 2025, with initial efficacy... ► Artikel lesen | |
| PALVELLA THERAPEUTICS | 11,950 | 0,00 % | XFRA CAPITAL ADJUSTMENT INFORMATION - 17.12.2024 | Das Instrument 14B NO0010776990 HUDDLY AS -,000625 EQUITY wird ex Kapitalmassnahme gehandelt am 17.12.2024 The instrument 14B NO0010776990 HUDDLY AS -,000625 EQUITY is traded ex capital adjustment on... ► Artikel lesen | |
| DIANTHUS THERAPEUTICS | 22,000 | -4,35 % | Forecasting The Future: 5 Analyst Projections For Dianthus Therapeutics | ||
| JOUNCE THERAPEUTICS | - | - | Taboola, Inc.: Taboola Partners with Jounce Media to Verify Ad Inventory is Free From Made for Advertising (MFA) Properties | ||
| LENZ THERAPEUTICS | 32,630 | +7,16 % | LENZ Therapeutics, Inc.: LENZ Therapeutics Reports Third Quarter 2024 Financial Results | New Drug Application (NDA) for LNZ100 for treatment of presbyopia accepted for review by the U.S. Food and Drug Administration (FDA); PDUFA target action date of August 8, 2025 CORXEL and... ► Artikel lesen | |
| TOURMALINE BIO | 20,680 | +1,67 % | Tourmaline Bio, Inc.: Tourmaline Bio Highlights Cardiovascular Inflammation Focus and Announces Key Clinical and Strategic Updates at Investor Day | - Phase 2 TRANQUILITY trial surpasses enrollment target, with 143 total patients enrolled; topline data expected in second quarter of 2025 - - Deepak L. Bhatt, MD, MPH, MBA and Dipender Gill, MD,... ► Artikel lesen | |
| ADMA BIOLOGICS | 17,400 | -2,68 % | ADMA Biologics, Inc.: ADMA Biologics Announces Partial Paydown of Senior Term Loan Credit Facility | ||
| QIAGEN | 42,900 | +0,04 % | Sartorius, Qiagen, Siemens Energy, DHL Group, Adidas, Puma: DAX-Ausblick | Nach seiner jüngsten Rekordjagd hat der DAX in der abgelaufenen Woche etwas Luft geholt. Unter dem Strich legte das größte deutsche Börsenbarometer trotzdem 21 Punkte zu und schloss mit knapp 20.406... ► Artikel lesen | |
| PRAXIS PRECISION MEDICINES | 76,52 | +5,05 % | Praxis Precision Medicines, Inc.: Praxis Precision Medicines Announces Rare Pediatric Disease Designation Granted for Relutrigine in Dravet Syndrome | Dravet syndrome is a genetic developmental and epileptic encephalopathy (DEE) often caused by a mutation in SCN1A This is the third Rare Pediatric Disease Designation for relutrigine, adding to those... ► Artikel lesen | |
| ARCUTIS BIOTHERAPEUTICS | 14,990 | +6,24 % | Arcutis Biotherapeutics, Inc.: Arcutis Submits ZORYVE (roflumilast) Cream 0.05% Supplemental New Drug Application to the FDA for the Treatment of Children Aged 2 to 5 with Mild to Moderate Atopic Dermatitis | ZORYVE cream 0.05% provided meaningful disease clearance and rapid reduction in itch in pivotal trialsRoflumilast cream was well tolerated and demonstrated a favorable safety and tolerability profile... ► Artikel lesen | |
| EVOTEC | 8,405 | +1,08 % | Evotec Aktie: Beeindruckende Entwicklung! | Die Evotec-Aktie zeigt im aktuellen Börsenumfeld erste Anzeichen einer Stabilisierung. Nach einem herausfordernden Jahr 2024 mit einem Rückgang von fast 60 Prozent konnte sich das Papier zuletzt von... ► Artikel lesen | |
| VIR BIOTECHNOLOGY | 7,340 | -0,27 % | Vir Biotechnology Reports Third Quarter 2024 Financial Results and Provides Corporate Update | SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today provided a corporate update and reported financial results for the third quarter ended September 30, 2024.
"This quarter... ► Artikel lesen | |
| CELCUITY | 12,460 | +3,83 % | Celcuity Inc.: Celcuity Presents Overall Survival Data from Phase 1b Study Evaluating Gedatolisib in Combination with Palbociclib and Endocrine Therapy at the 2024 San Antonio Breast Cancer Symposium | Median overall survival (OS) among patients with HR+, HER2- advanced breast cancer who were treatment-naïve in the advanced setting was 77.3 months Median OS among patients previously treated with... ► Artikel lesen | |
| CONTINEUM THERAPEUTICS | 13,500 | +1,12 % | Contineum Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights | SAN DIEGO--(BUSINESS WIRE)--Contineum Therapeutics, Inc. (Nasdaq: CTNM), a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies that... ► Artikel lesen | |
| BIONTECH | 108,60 | +0,09 % | Abstieg und Hoffnung: So steht es um den BioNTech-Konkurrenten Moderna | Die Aktie von Moderna hat in den vergangenen zwölf Monaten eine enttäuschende Entwicklung hingelegt. Im Nasdaq 100 gehört sie in diesem Zeitraum zu den zwei schlechtesten Werten. Nun muss sie den Index... ► Artikel lesen |
Das Unternehmen SPYRE THERAPEUTICS INC kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell 0,00 % bei einem Aktienkurs von 23,000 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu SPYRE THERAPEUTICS INC finden Sie auf Wallstreet Online.
